Adarsh International Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Adarsh International Pharmaceutical Export Portfolio Dataset — 2 Products, $471.6K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Adarsh International — Pharmaceutical Exporter Profile (2026) | 2 Products, $471.6K Trade | TransData Nexus

Adarsh International

Indian Pharmaceutical Exporter · Ayurvedic & Herbal Products Specialist · $471.6K Total Trade · DGFT Verified

Adarsh International is an Indian pharmaceutical exporter with a total trade value of $471.6K across 2 products in 1 therapeutic categories. Based on 669 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Herbal ($469.7K), Gutika ($1.9K), .

Adarsh International — Export Portfolio & Destination Treemap

Adarsh International pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Adarsh International? — Company Overview & Market Position

Adarsh International is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 1995, the company is headquartered in Indore, Madhya Pradesh, India. It operates as a public limited company with the Corporate Identification Number (CIN) U01514MP1995PLC009260. The authorized capital is ₹1.00 crore, with a paid-up capital of ₹1.01 lakh. The company is unlisted and has a compliant status. The latest Annual General Meeting (AGM) occurred on 30 September 2025, with the balance sheet filed on 31 March 2025.

What Does Adarsh International Export? — Product Portfolio Analysis

Top Products by Export Value

1Herbal$469.7K 2Gutika$1.9K

Adarsh International Therapeutic Categories — 1 Specializations

Adarsh International operates across 1 therapeutic categories, with representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.

Product Portfolio — Top 2 by Export Value

Adarsh International exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Herbal	Ayurvedic & Herbal Products	$469.7K	665	2.5%	8
2	Gutika	Ayurvedic & Herbal Products	$1.9K	4	1.5%	13

Adarsh International exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $471.6K. The top category is Ayurvedic & Herbal Products (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Adarsh International — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Adarsh International operates manufacturing facilities in Indore, Madhya Pradesh, India. Specific details regarding plant locations, capacities, and specializations are not publicly disclosed. The company's product portfolio is concentrated in Ayurvedic and Herbal Products, indicating a focus on traditional medicine formulations. The top five products exported are Herbal products, accounting for $470K in export value and a 2.5% market share, and Gutika, contributing $2K in export value and a 1.5% market share. This concentration suggests a strategic emphasis on herbal and Ayurvedic formulations.

3Key Leadership

The leadership team of Adarsh International includes:

Pushpa Jaju: Director
Prem Prakash Jaju: Whole-Time Director
Anita Jaju: Director
Ram Awatar Jaju: Whole-Time Director

These individuals have been associated with the company since its inception in 1995, indicating a stable and experienced leadership team.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Adarsh International Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Adarsh International's presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan is not explicitly detailed in the available sources. The company's export data indicates a focus on Ayurvedic and Herbal Products, which may face regulatory challenges in these markets due to stringent standards for herbal and traditional medicines. Without specific regulatory filings, approvals, or market access information, it is challenging to assess the company's standing in these regions.

2Emerging Markets

Adarsh International's export data does not provide specific insights into its penetration in emerging markets such as Africa, Latin America, and Southeast Asia. The company's focus on Ayurvedic and Herbal Products suggests potential opportunities in these regions, where traditional medicine is prevalent. However, without information on WHO prequalification or other certifications, it is difficult to determine the company's ability to access these markets.

3Geographic Strategy

Adarsh International's export data reveals a portfolio concentration, with the top five products accounting for 100% of the export value. This indicates a strategic focus on Ayurvedic and Herbal Products. The lack of diversification in product offerings may expose the company to risks associated with market fluctuations and regulatory changes affecting these specific product categories. A more diversified product portfolio could mitigate such risks and enhance the company's strategic position.

Adarsh International — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Adarsh International's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export data does not indicate a significant presence in the U.S. market, which may be due to regulatory challenges associated with Ayurvedic and Herbal Products. Without detailed FDA-related information, it is challenging to assess the company's compliance and standing in the U.S. market.

2WHO & EU GMP

There is no publicly available information regarding Adarsh International's WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines (EDQM) status. The company's export data indicates a focus on Ayurvedic and Herbal Products, which may face challenges in obtaining such certifications due to stringent regulatory requirements. Without these certifications, the company's ability to access certain international markets may be limited.

3CDSCO & Indian Regulatory

Adarsh International — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Adarsh International operates in the Ayurvedic and Herbal Products segment, which is characterized by a diverse range of competitors, including both large pharmaceutical companies and specialized herbal product manufacturers. The company's export data indicates a focus on herbal products, with a market share of 2.5%, and Gutika, with a market share of 1.5%. While these figures suggest a presence in the market, the company's relatively small market share indicates that it faces significant competition. A more detailed analysis of competitors' market shares and product offerings would provide a clearer picture of Adarsh International's competitive position.

2Key Differentiators

Adarsh International's key differentiators include its focus on Ayurvedic and Herbal Products, catering to the growing global demand for natural and traditional medicines. The company's long-standing presence since 1995 and experienced leadership team further contribute to its credibility and reliability. However, the lack of product diversification and limited market share may pose challenges in differentiating the company from competitors.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Adarsh International as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Adarsh International's track record in terms of export volume and consistency is not fully detailed in the available sources. The company's export data indicates a total export value of $472K USD across 669 shipments, with a focus on two products in the Ayurvedic and Herbal Products category. This suggests a niche market presence with a concentrated product offering. The company's compliant status and absence of regulatory actions indicate reliability in its operations. However, the lack of product diversification and limited market share may affect its competitiveness in the broader pharmaceutical export market.

2Certifications to Verify

Importers should verify the following certifications when considering Adarsh International as a supplier:

FDA Facility Registration: To ensure compliance with U.S. regulations. Verification can be done through the FDA's official website.

WHO-GMP Certification: To confirm adherence to World Health Organization Good Manufacturing Practices. Verification can be done through the WHO's official website.

Frequently Asked Questions — Adarsh International

How many pharmaceutical products does Adarsh International export from India?

Adarsh International exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Herbal ($469.7K), Gutika ($1.9K). Total export value is $471.6K.

What is Adarsh International's total pharmaceutical export value?

Adarsh International's total pharmaceutical export value is $471.6K, based on 669 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Adarsh International cover?

Adarsh International exports across 1 therapeutic categories. The largest are Ayurvedic & Herbal Products (100.0%, 2 products).

Get Full Adarsh International Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.